Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Harris

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer Chemotherapy and Pharmacology|May 19, 2019
Exposure time versus cytotoxicity for anticancer agentsDavid M Evans, Jianwen Fang, Thomas Silvers, et al.
Journal of the National Cancer Institute|June 2, 2016
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionEric Polley, Mark Kunkel, David Evans, et al.
Biochemical Pharmacology|July 16, 2017
Characterization of potent and selective iodonium-class inhibitors of NADPH oxidasesJiamo Lu, Prabhakar Risbood, Charles T Kane, et al.
Oncotarget|October 22, 2021
ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomideLara H El Touny, Curtis Hose, John Connelly, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer Chemotherapy and Pharmacology|May 19, 2019
Exposure time versus cytotoxicity for anticancer agentsDavid M Evans, Jianwen Fang, Thomas Silvers, et al.
Journal of the National Cancer Institute|June 2, 2016
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionEric Polley, Mark Kunkel, David Evans, et al.
Biochemical Pharmacology|July 16, 2017
Characterization of potent and selective iodonium-class inhibitors of NADPH oxidasesJiamo Lu, Prabhakar Risbood, Charles T Kane, et al.
Oncotarget|October 22, 2021
ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomideLara H El Touny, Curtis Hose, John Connelly, et al.
Cancer Research|October 26, 2018
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line PanelAnne Monks, Yingdong Zhao, Curtis Hose, et al.
Pageof 2